Group 1 - The Q1 results in Diversified Tools and Pharma Services showed modest outperformance despite multiple guidance revisions [1] - The revisions reflect a more challenging macroeconomic environment, including tariffs and NIH-related disruptions [1] - There is a more cautious stance on biopharma spending noted in the current analysis [1]